Skip to content

Study · In vitro (cells) · mouse · 2014

2 results

Cytoprotective mechanisms of erythropoietin and erythropoietin derivatives in peripheral arterial disease

Yu SR

University College London (University of London)1 Jan 2014

PepBankPUB-90096308
Source linkAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In murine and human myoblasts under simulated ischaemia, ARA‑290 (like EPO) significantly improved cell function and survival.

    In plain wordsIn muscle cells under simulated lack of blood flow, ARA‑290 improved cell function and survival compared with ischaemia alone.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    IncreaseMyoblast function and survival under simulated ischaemia
    Study

    mouse and humann: not reported in source

    Simulated ischaemia in C2C12 myoblasts and human skeletal myoblasts from CLI and control donors
    Comparator
    Simulated ischaemia alone
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Addition of EPO or ARA-290 demonstrated significant improvements in function and survival and utilised JAK2/STAT3, PI3k/Akt and NF!B signalling molecules.
    1 context sentence
    Summary · context
    The effect of EPO and ARA-290 in mediating cytoprotection in an in vitro simulated ischaemia model of skeletal muscle was assessed firstly in the immortalised murine C2C12 myoblast cell line and subsequently in skeletal myoblasts isolated from CLI and control donors.
  2. 02LabIn vitro (cells)Mechanism

    In murine and human myoblasts under simulated ischaemia, the protective effect of ARA‑290 (like EPO) used JAK2/STAT3, PI3k/Akt and NF-kB signalling molecules.

    In plain wordsIn muscle cells, ARA‑290 acted through the JAK2/STAT3, PI3k/Akt and NF-kB signalling pathways.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    Not applicableSignalling pathways used by ARA-290
    Study

    mouse and humann: not reported in source

    Simulated ischaemia in C2C12 myoblasts and human skeletal myoblasts from CLI and control donors
    Outcome group
    Receptor activity and mechanism · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    utilised JAK2/STAT3, PI3k/Akt and NF!B signalling molecules.
    1 context sentence
    Summary · context
    The effect of EPO and ARA-290 in mediating cytoprotection in an in vitro simulated ischaemia model of skeletal muscle was assessed firstly in the immortalised murine C2C12 myoblast cell line and subsequently in skeletal myoblasts isolated from CLI and control donors.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 10:21 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.